Perioperative Multimodal Analgesia for Supratentorial Craniotomy

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from Beijing Tiantan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 6 more changesShow less
    • Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2026 to Mar 9, 2026
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints expanded, about 14 words
    • Study description shortened, about 57 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This randomized clinical trial aims to evaluate the effectiveness of scalp nerve blocks and dexmedetomidine in reducing opioid use and preventing postoperative delirium in patients undergoing supratentorial brain tumor surgery. A total of 2000 patients will be randomly assigned to one of four groups, receiving either active treatments, placebos, or their combinations.
Trial Details
NCT Number NCT07441421
Lead Sponsor Beijing Tiantan Hospital
Conditions
(from sponsor)		 Postoperative Pain, Analgesia, Supratentorial Brain Tumor
Related terms Agnosia, Postoperative Pain
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov